Radiopharmaceuticals are what you get when you take a targeting ligand โ an antibody, peptide, or small molecule โ and attach a radioactive isotope to it, allowing the radiation to be delivered precisely to tumor cells rather than to the body generally. The concept isn't new: iodine-131 for thyroid cancer has been used for decades. What changed is the ability to conjugate beta and alpha emitters to highly specific targeting vectors, validated by PSMA PET imaging. The VISION trial of lutetium-177 PSMA-617 in metastatic castration-resistant prostate cancer showed a radiographic progression-free survival hazard ratio of 0.40 โ a magnitude of effect that doesn't happen often in late-line oncology. The field is now at an inflection point between two approved products and a pipeline of actinium-225 alpha emitters that may be substantially more potent.
This article is for informational purposes only and does not constitute medical advice. Radiopharmaceutical therapy requires specialized nuclear medicine facilities and is currently approved only for specific indications. Consult your oncologist or urologist for guidance specific to your diagnosis.
Summary
Two lutetium-177 radiopharmaceuticals are FDA-approved: Pluvicto (Lu-177 PSMA-617) for mCRPC (VISION: rPFS HR 0.40, OS HR 0.62) and Lutathera (Lu-177 DOTATATE) for somatostatin receptor-positive GEP-NETs (NETTER-1: PFS HR 0.18). PSMA PET/CT imaging is required before Pluvicto to confirm PSMA-positive disease. The 2026 pipeline includes actinium-225 PSMA (ฮฑ-emitter, higher potency, shorter range โ potentially useful in micro-metastatic disease), AstraZeneca/Fusion FPI-2265 (Ac-225 PSMA, Phase 3), and multiple programs in breast, lung, and hematologic cancers using novel targeting vectors. Radioligand therapy requires certified nuclear medicine facilities. Manufacturing capacity has been a rate-limiting factor for access.
ClinicalMetric Analysis
- PSMA expression heterogeneity means not all "PSMA-positive" patients respond equally, and the qualification threshold matters. VISION required PSMA PET uptake โฅ normal liver on at least one lesion. This is a reasonably permissive threshold. Post-hoc analyses suggest that patients with higher PSMA expression (uptake significantly above liver) derive more benefit. The upcoming PSMAddition and SPLASH trials (evaluating Lu-177 PSMA in earlier disease settings โ not just post-cabazitaxel) will use different eligibility thresholds, and results will not be directly comparable to VISION without understanding the patient population's PSMA expression distribution. Imaging criteria are an active variable in trial design for radiopharmaceuticals in a way that lab values rarely are for other therapies.
- Alpha emitters (Ac-225) have different physics than beta emitters (Lu-177), which translates to different clinical applications. Beta particles from Lu-177 have a tissue range of approximately 1.6 mm โ enough to treat tumor masses but enough to also irradiate adjacent normal tissue. Alpha particles from Ac-225 have a range of 50โ80 microns (3โ7 cell diameters) and about 100ร the linear energy transfer of beta particles. Alpha emitters cause double-strand DNA breaks that are far harder to repair than beta-induced single-strand damage. The short range is a feature for micrometastatic disease and circulating tumor cells; it's a limitation for large tumor masses where the radiation doesn't penetrate deeply. The clinical hypothesis for actinium-225 PSMA is that it will be superior in patients with bone-dominant small-volume disease โ which requires the trials to select those patients rather than treating all PSMA-positive mCRPC identically.
- Manufacturing capacity for Pluvicto has been a real access problem that the clinical community underestimated at approval. Novartis received FDA approval for Pluvicto in March 2022 and struggled immediately to meet demand. The issue is the supply of lutetium-177 itself (produced in nuclear reactors) and the short half-life (6.6 days) that requires just-in-time manufacturing close to treatment centers. Sites that couldn't be certified in time couldn't treat eligible patients. As of 2026, Novartis has expanded manufacturing sites, and patient access has improved, but the experience highlighted that for radiopharmaceuticals, supply chain and infrastructure planning needs to be part of the regulatory submission strategy, not an afterthought. This lesson will shape how the actinium-225 programs approach launch planning.
VISION Trial: The Data That Defined Radioligand Therapy in Prostate Cancer
The VISION trial (NCT03511664) enrolled 831 patients with PSMA-positive, progressive mCRPC who had received โฅ1 ARSI (enzalutamide or abiraterone) and 1โ2 prior taxane regimens. Patients were randomized 2:1 to Lu-177 PSMA-617 plus protocol-permitted standard of care versus standard of care alone.
Primary endpoints: radiographic progression-free survival (rPFS) and overall survival (OS). Results: rPFS HR 0.40 (95% CI 0.29โ0.57), median 8.7 vs 3.4 months. OS HR 0.62 (95% CI 0.52โ0.74), median 15.3 vs 11.3 months. Imaging response rate: 46% vs 7%. These results led to FDA approval in March 2022 as Pluvicto (vipivotide tetraxetan).
Safety: Grade 3+ adverse events more common with Lu-177 PSMA-617: dry mouth (1%), anemia (13%), fatigue (9%). No unexpected toxicities. Salivary gland accumulation (PSMA is expressed in salivary glands) causes the dry mouth and, in higher doses, salivary gland dysfunction. Dose fractionation strategies are being tested to reduce salivary gland exposure without sacrificing efficacy.
NETTER-1 and Lutathera: The NET Standard
Lutathera (lutetium-177 DOTATATE) targets somatostatin receptor 2, overexpressed in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The NETTER-1 Phase 3 trial randomized midgut NET patients (SRS-positive, progressive on octreotide LAR) to Lu-177 DOTATATE + octreotide LAR versus high-dose octreotide LAR alone. PFS HR 0.18 (median not reached vs 8.4 months at primary analysis), overall response rate 18% vs 3%. The PFS hazard ratio of 0.18 is one of the strongest in NET oncology.
FDA approved Lutathera in January 2018. It requires somatostatin receptor imaging (Ga-68 DOTATATE PET) to confirm receptor positivity before treatment. Amino acid infusion is co-administered to reduce renal tubular reabsorption of Lu-177 and protect kidney function โ a requirement that adds complexity to administration but meaningfully reduces nephrotoxicity.
The Actinium-225 Pipeline
FPI-2265 (Ac-225 PSMA-1012, AstraZeneca/Fusion): Phase 3 (ARROW, NCT05150236) in mCRPC, comparing Ac-225 PSMA vs Lu-177 PSMA-617. This is a head-to-head alpha vs beta comparison that will generate the definitive answer on whether the higher-potency alpha emitter produces meaningfully better outcomes. Primary endpoint: OS. Enrollment ongoing.
PSMA-617 with Ac-225 (multiple sponsors): The same targeting vector as Pluvicto, but conjugated to Ac-225 instead of Lu-177. Phase 1 data from Heidelberg and other centers showed responses in patients who had progressed on Lu-177 PSMA-617 โ suggesting the alpha emitter can overcome resistance to the beta emitter, likely through the more lethal DNA damage mechanism.
Beyond prostate cancer: programs are targeting FAP (fibroblast activation protein, expressed in tumor stroma across many cancer types), HER2 (Ac-225 trastuzumab), and SSTR2 in NETs with Ac-225 DOTATATE. The FAP-targeting radioligands are particularly interesting because FAP is expressed on cancer-associated fibroblasts across many tumor types, potentially enabling a tumor-microenvironment-targeted approach that doesn't depend on tumor cell antigen expression.
Accessing Radiopharmaceutical Trials
Radiopharmaceutical clinical trials are conducted at specialized nuclear medicine centers โ typically large academic medical centers with cyclotron or reactor-produced isotope supply chains, certified hot labs, and radiation safety infrastructure. Eligibility for PSMA-targeted trials requires PSMA PET/CT imaging (Ga-68 PSMA-11 or F-18 DCFPyL) confirming PSMA-positive disease, which must be performed at a qualified imaging site. Standard exclusions include previous radiopharmaceutical therapy (unless specifically allowed), serious renal impairment (GFR <30), bone marrow compromise, and inability to comply with radiation safety precautions (isolation requirements for beta-emitting isotopes). Most trials require patients to temporarily reduce contact with pregnant women and young children for 2โ3 days post-infusion, which affects patient selection in practice.